However, this observation was inconsistent with our results, which presented that mutation in either BRAFV600E or KRAS was not related to the adverse clinicopathological features accompanied by advanced lymph node metastasis and III-IV disease stages. This evidence concerns the gene KRAS and metastatic malignant neoplasm in the lymph nodes.